Search

Your search keyword '"WEGER, Wolfgang"' showing total 15 results
Start Over Author "WEGER, Wolfgang" Publication Year Range Last 3 years
15 results on '"WEGER, Wolfgang"'

3. Mast cells express IL17A, IL17F and RORC, are activated and persist with IL-17 production in resolved skin of patients with chronic plaque-type psoriasis

Author

Benezeder, Theresa, primary, Bordag, Natalie, additional, Woltsche, Johannes, additional, Teufelberger, Andrea, additional, Perchthaler, Isabella, additional, Weger, Wolfgang, additional, Salmhofer, Wolfgang, additional, Gruber-Wackernagel, Alexandra, additional, Painsi, Clemens, additional, Zhan, Qian, additional, El-Heliebi, Amin, additional, Babina, Magda, additional, Clark, Rachael, additional, and Wolf, Peter, additional

Published
2024
Full Text
View/download PDF

4. Entwicklung der Patientencharakteristika und der Wirksamkeit der Biologika‐Therapie bei Patienten des Österreichischen Psoriasis‐Registers von 2004 bis 2022

Author

Graier, Thomas, primary, Salmhofer, Wolfgang, additional, Jonak, Constanze, additional, Weger, Wolfgang, additional, Zikeli, Claudia, additional, Gruber, Barbara, additional, Sator, Paul, additional, Prillinger, Knut, additional, Mlynek, Alexander, additional, Schütz‐Bergmayr, Martina, additional, Richter, Leo, additional, Ratzinger, Gudrun, additional, Sassmann, Christoph, additional, Painsi, Clemens, additional, Häring, Nina, additional, Wippel‐Slupetzky, Katharina, additional, Skvara, Hans, additional, Trattner, Hannes, additional, Inzinger, Martin, additional, Bangert, Christina, additional, Ellersdorfer, Christina, additional, Falkensteiner, Katharina, additional, Sadoghi, Birgit, additional, Gruber‐Wackernagel, Alexandra, additional, Hofer, Angelika, additional, Legat, Franz, additional, Lange‐Asschenfeldt, Bernhard, additional, Schmuth, Matthias, additional, Vujic, Igor, additional, Hötzenecker, Wolfram, additional, Saxinger, Werner, additional, Müllegger, Robert, additional, Quehenberger, Franz, additional, and Wolf, Peter, additional

Published
2023
Full Text
View/download PDF

5. Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004–2022

Author

Graier, Thomas, primary, Salmhofer, Wolfgang, additional, Jonak, Constanze, additional, Weger, Wolfgang, additional, Zikeli, Claudia, additional, Gruber, Barbara, additional, Sator, Paul, additional, Prillinger, Knut, additional, Mlynek, Alexander, additional, Schütz‐Bergmayr, Martina, additional, Richter, Leo, additional, Ratzinger, Gudrun, additional, Sassmann, Christoph, additional, Painsi, Clemens, additional, Häring, Nina, additional, Wippel‐Slupetzky, Katharina, additional, Skvara, Hans, additional, Trattner, Hannes, additional, Inzinger, Martin, additional, Bangert, Christina, additional, Ellersdorfer, Christina, additional, Falkensteiner, Katharina, additional, Sadoghi, Birgit, additional, Gruber‐Wackernagel, Alexandra, additional, Hofer, Angelika, additional, Legat, Franz, additional, Lange‐Asschenfeldt, Bernhard, additional, Schmuth, Matthias, additional, Vujic, Igor, additional, Hötzenecker, Wolfram, additional, Saxinger, Werner, additional, Müllegger, Robert, additional, Quehenberger, Franz, additional, and Wolf, Peter, additional

Published
2023
Full Text
View/download PDF

6. Ungewöhnliche Präsentation einer Psoriasis vulgaris bei einem 11-jährigen Patienten

Author

Gruber, Viktoria, Weger, Wolfgang, Cerroni, Lorenzo, and Binder, Barbara

Abstract

Die Psoriasis vulgaris tritt mit einer Prävalenz von bis zu 2 % im Kindes- und Jugendalter auf. Größtenteils wird die Diagnose klinisch gestellt. Wir berichten über einen pädiatrischen Patienten, welcher uns aufgrund der für eine Psoriasis vulgaris eher untypischen Lokalisation vor eine diagnostische Herausforderung stellte. Diskutiert werden die wichtigsten Differenzialdiagnosen der verschiedenen Psoriasisformen sowie die aktuellen Therapieempfehlungen im Kindes- und Jugendalter.

Published
2024
Full Text
View/download PDF

8. Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study

Author

Jonak, Constanze, primary, Göttfried, Isolde, additional, Perl-Convalexius, Sylvia, additional, Gruber, Barbara, additional, Schütz-Bergmayr, Martina, additional, Vujic, Igor, additional, Weger, Wolfgang, additional, Schicher, Nikolaus, additional, Semlin, Lydia, additional, Hemetsberger, Margit, additional, Cordey, Myriam, additional, and Sator, Paul, additional

Published
2023
Full Text
View/download PDF

9. sj-docx-1-taj-10.1177_20406223231152785 – Supplemental material for Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study

Author

Jonak, Constanze, Göttfried, Isolde, Perl-Convalexius, Sylvia, Gruber, Barbara, Schütz-Bergmayr, Martina, Vujic, Igor, Weger, Wolfgang, Schicher, Nikolaus, Semlin, Lydia, Hemetsberger, Margit, Cordey, Myriam, and Sator, Paul

Subjects
FOS: Psychology, 110203 Respiratory Diseases, FOS: Clinical medicine, Cardiology, 170199 Psychology not elsewhere classified, 111702 Aged Health Care, FOS: Health sciences, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 110308 Geriatrics and Gerontology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-1-taj-10.1177_20406223231152785 for Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study by Constanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, Barbara Gruber, Martina Schütz-Bergmayr, Igor Vujic, Wolfgang Weger, Nikolaus Schicher, Lydia Semlin, Margit Hemetsberger, Myriam Cordey and Paul Sator in Therapeutic Advances in Chronic Disease

Published
2023
Full Text
View/download PDF

10. sj-docx-2-taj-10.1177_20406223231152785 – Supplemental material for Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study

Author

Jonak, Constanze, Göttfried, Isolde, Perl-Convalexius, Sylvia, Gruber, Barbara, Schütz-Bergmayr, Martina, Vujic, Igor, Weger, Wolfgang, Schicher, Nikolaus, Semlin, Lydia, Hemetsberger, Margit, Cordey, Myriam, and Sator, Paul

Subjects
FOS: Psychology, 110203 Respiratory Diseases, FOS: Clinical medicine, Cardiology, 170199 Psychology not elsewhere classified, 111702 Aged Health Care, FOS: Health sciences, 110319 Psychiatry (incl. Psychotherapy), 110306 Endocrinology, 110308 Geriatrics and Gerontology, 111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified, 110904 Neurology and Neuromuscular Diseases
Abstract

Supplemental material, sj-docx-2-taj-10.1177_20406223231152785 for Characteristics and outcomes of patients with psoriasis treated with apremilast in the real-world in Austria – results the APPRECIATE study by Constanze Jonak, Isolde Göttfried, Sylvia Perl-Convalexius, Barbara Gruber, Martina Schütz-Bergmayr, Igor Vujic, Wolfgang Weger, Nikolaus Schicher, Lydia Semlin, Margit Hemetsberger, Myriam Cordey and Paul Sator in Therapeutic Advances in Chronic Disease

Published
2023
Full Text
View/download PDF

13. Mast cells express IL17A, IL17F and RORC, are activated and persist with IL-17 production in resolved skin of patients with chronic plaque-type psoriasis.

Author

Benezeder T, Bordag N, Woltsche J, Teufelberger A, Perchthaler I, Weger W, Salmhofer W, Gruber-Wackernagel A, Painsi C, Zhan Q, El-Heliebi A, Babina M, Clark R, and Wolf P

Abstract

Little is known about IL-17 expression in psoriasis and the actual cellular source of IL-17 remains incompletely defined. We show that high numbers of IL-17 + mast cells persisted in resolved lesions after treatment (anti-IL-17A, anti-IL-23, UVB or topical dithranol) and correlated inversely with the time span in remission. IL-17 + mast cells were found in T cell-rich areas and often close to resident memory T cells (T rm ) in active psoriasis and resolved lesional skin. Digital cytometry by deconvolution of RNA-seq data showed that activated mast cells were increased in psoriatic skin, while resting mast cells were almost absent and both returned to normal levels after treatment. When primary human skin mast cells were stimulated with T cell cytokines (TNFα, IL-22 and IFNγ), they responded by releasing more IL-17A, as measured by ELISA. In situ mRNA detection using padlock probes specific for transcript variants of IL17A, IL17F , and RORC (encoding the Th17 transcription factor RORγt) revealed positive mRNA signals for IL17A, IL17F , and RORCin tryptase + cells, demonstrating that mast cells have the transcriptional machinery to actively produce IL-17. Mast cells thus belong to the center of the IL-23/IL-17 axis and high numbers of IL-17 + mast cells predict an earlier disease recurrence., Competing Interests: The authors declare no competing financial interests.

Published
2024
Full Text
View/download PDF

14. Evolution of characteristics and biologic treatment effectiveness in patients of the Austrian psoriasis registry from 2004-2022.

Author

Graier T, Salmhofer W, Jonak C, Weger W, Zikeli C, Gruber B, Sator P, Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Sassmann C, Painsi C, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Inzinger M, Bangert C, Ellersdorfer C, Falkensteiner K, Sadoghi B, Gruber-Wackernagel A, Hofer A, Legat F, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hötzenecker W, Saxinger W, Müllegger R, Quehenberger F, and Wolf P

Subjects
Humans, Female, Austria epidemiology, Treatment Outcome, Registries, Severity of Illness Index, Psoriasis drug therapy, Psoriasis epidemiology, Biological Products therapeutic use
Abstract

Background and Objectives: This study analyzed the extent to which the recent introduction of more effective treatments has led to an improvement in real-world psoriasis patients., Patients and Methods: Patient characteristics and the first-year treatment effectiveness in biologic-naive patients have been analyzed since 2004 until now, irrespective of treatment switches., Results: Data from 2,729 patients were eligible for this analysis. The proportion of female patients increased significantly over the years from 29.9% to 36.2% (p < 0.028), while the number of patients with psoriatic arthritis declined from 36.6% to 30.0% (p < 0.001). Moreover, the duration of psoriatic disease and PASI at the start of the treatment significantly decreased. Last observation carrief forward (LOCF) analysis indicated that PASI 90 response increased from 18.9 to 44.6% at 3 months and from 32.9 to 66.8% at 12 months after treatment started. Similary, the PASI ≤ 3 rates increased from 33.2% to 66.0% at 3 months and from 41.9% to 78.9% at 12 months after the treatment started., Conclusions: The continuous introduction of more efficient biologics has led to significant improvements in patient care and clinical outcomes. Though one out of three to five patients, depending on the endpoint selected, nowadays still does not achieve an entirely satisfactory treatment response (i.e., PASI 90 or PASI ≤ 3)., (© 2023 The Authors. Journal der Deutschen Dermatologischen Gesellschaft published by John Wiley & Sons Ltd on behalf of Deutsche Dermatologische Gesellschaft.)

Published
2023
Full Text
View/download PDF

15. Entwicklung der Patientencharakteristika und der Wirksamkeit der Biologika-Therapie bei Patienten des Österreichischen Psoriasis-Registers von 2004 bis 2022.

Author

Graier T, Salmhofer W, Jonak C, Weger W, Zikeli C, Gruber B, Sator P, Prillinger K, Mlynek A, Schütz-Bergmayr M, Richter L, Ratzinger G, Sassmann C, Painsi C, Häring N, Wippel-Slupetzky K, Skvara H, Trattner H, Inzinger M, Bangert C, Ellersdorfer C, Falkensteiner K, Sadoghi B, Gruber-Wackernagel A, Hofer A, Legat F, Lange-Asschenfeldt B, Schmuth M, Vujic I, Hötzenecker W, Saxinger W, Müllegger R, Quehenberger F, and Wolf P

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results